Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Opus Genetics, Inc. issued 7,374,632 shares of its Series B Non-Voting Convertible Preferred Stock of preferred stock to certain purchasers for $3.39 per share for an aggregate purchase price of approximately $25.0 million.
- Security
- preferred stock
- Shares
- 7,374,632 shares of its Series B Non-Voting Convertible Preferred Stock
- Purchaser
- certain purchasers
- Consideration
- $3.39 per share for an aggregate purchase price of approximately $25.0 million
Exact text from the filing
The Private Placement closed on February 18, 2026. Pursuant to the Securities Purchase Agreement, the Purchasers purchased the Series B Preferred Stock at a purchase price of $3.39 per share for an aggregate purchase price of approximately $25.0 million. The Company expects to use the net proceeds from the Private Placement to advance its gene therapy
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
Opus Genetics, Inc. entered into Registration Rights Agreement with the Purchasers valued at Company will register the resale of shares of Common Stock issuable upon conversion of Series B Pref (effective 2026-02-18).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- the Purchasers
- Value
- Company will register the resale of shares of Common Stock issuable upon conversion of Series B Pref
- Effective
- 2026-02-18
Exact text from the filing
In connection with the Private Placement, the Company also entered into a Registration Rights Agreement, dated February 18, 2026 (the “Registration Rights Agreement”), with the Purchasers, which provides that the Company will register the resale of the shares of Common Stock issuable upon conversion of the Series B Preferred Stock.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
Opus Genetics, Inc. entered into Securities Purchase Agreement with certain purchasers valued at Aggregate purchase price of approximately $25.0 million for 7,374,632 shares of Series B Non-Voting (effective 2026-02-13).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- certain purchasers
- Value
- Aggregate purchase price of approximately $25.0 million for 7,374,632 shares of Series B Non-Voting
- Effective
- 2026-02-13
Exact text from the filing
On February 13, 2026, Opus Genetics, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain purchasers (the “Purchasers”) for a private placement (the “Private Placement”) of an aggregate of 7,374,632 shares of its Series B Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the “Series B Preferred Stock”).
View on SEC.gov